Histiocytoses: emerging neoplasia behind inflammation

被引:141
作者
Haroche, Julien [1 ]
Cohen-Aubart, Fleur [1 ]
Rollins, Barret J. [4 ]
Donadieu, Jean [5 ]
Charlotte, Frederic [2 ]
Idbaih, Ahmed [3 ]
Vaglio, Augusto [6 ]
Abdel-Wahab, Omar [7 ]
Emile, Jean-Francois [8 ,9 ,10 ]
Amoura, Zahir [1 ]
机构
[1] Hop La Pitie Salpetriere, Serv Med Interne 2, Ctr Natl Reference Malad Auto Immunes Syst Rares, Inst E3M, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, AP HP, Serv Anatomocytopathol, Paris, France
[3] Hop La Pitie Salpetriere, AP HP, Serv Neurol Mazarin, Paris, France
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Hop Trousseau, AP HP, Serv Hematol, Paris, France
[6] Univ Hosp, Nephrol Unit, Parma, Italy
[7] Mem Sloan Kettering Canc Ctr, Leukemia Serv, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[8] Ambroise Pare Hosp, AP HP, EA4340, Boulogne, France
[9] Ambroise Pare Hosp, AP HP, Dept Pathol, Boulogne, France
[10] Univ Versailles, Boulogne, France
关键词
LANGERHANS-CELL HISTIOCYTOSIS; ERDHEIM-CHESTER-DISEASE; ROSAI-DORFMAN-DISEASE; MASSIVE LYMPHADENOPATHY; SINUS HISTIOCYTOSIS; MONOCENTRIC SERIES; HIGH PREVALENCE; FOLLOW-UP; MUTATIONS; INVOLVEMENT;
D O I
10.1016/S1470-2045(17)30031-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histiocytoses are disorders characterised by inflammation and the accumulation of cells derived from the monocyte and macrophage lineages, which results in tissue damage. Although they are often considered rare disorders with protean clinical manifestations, considerable advances in the understanding of their genetics have led to increased clinical recognition of these conditions, and fuelled further insights into their pathogenesis. In this Review, we describe insights into the cells of origin, molecular pathology, clinical features, and treatment strategies for some of the most common histiocytic disorders, including Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease. With the discovery of recurrent mutations affecting the mitogen-activated protein kinase and mTOR-AKT pathways in some of these histiocytoses, our understanding of these diseases has now evolved from the concept of a primary inflammatory condition to that of a clonal neoplastic disease. This understanding has led to the development of effective mechanism-based therapeutic strategies for patients with histiocytic diseases.
引用
收藏
页码:E113 / E125
页数:13
相关论文
共 107 条
  • [11] Scintigraphic Diagnosis of Erdheim-Chester Disease
    Balink, Hans
    Hemmelder, Marc H.
    de Graaf, Wout
    Grond, Joris
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : E470 - E472
  • [12] BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
    Berres, Marie-Luise
    Lim, Karen Phaik Har
    Peters, Tricia
    Price, Jeremy
    Takizawa, Hitoshi
    Salmon, Helene
    Idoyaga, Juliana
    Ruzo, Albert
    Lupo, Philip J.
    Hicks, M. John
    Shih, Albert
    Simko, Stephen J.
    Abhyankar, Harshal
    Chakraborty, Rikhia
    Leboeuf, Marylene
    Beltrao, Monique
    Lira, Sergio A.
    Heym, Kenneth M.
    Clausen, Bjorn E.
    Bigley, Venetia
    Collin, Matthew
    Manz, Markus G.
    McClain, Kenneth
    Merad, Miriam
    Allen, Carl E.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (04) : 669 - 683
  • [13] Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-α
    Braiteh, F
    Boxrud, C
    Esmaeli, B
    Kurzrock, R
    [J]. BLOOD, 2005, 106 (09) : 2992 - 2994
  • [14] BROADBENT V, 1984, LANCET, V1, P253
  • [15] High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis
    Brown, Noah A.
    Furtado, Larissa V.
    Betz, Bryan L.
    Kiel, Mark J.
    Weigelin, Helmut C.
    Lim, Megan S.
    Elenitoba-Johnson, Kojo S. J.
    [J]. BLOOD, 2014, 124 (10) : 1655 - 1658
  • [16] Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis
    Chakraborty, Rikhia
    Hampton, Oliver A.
    Shen, Xiaoyun
    Simko, Stephen J.
    Shih, Albert
    Abhyankar, Harshal
    Lim, Karen Phaik Har
    Covington, Kyle R.
    Trevino, Lisa
    Dewal, Ninad
    Muzny, Donna M.
    Doddapaneni, Harshavardhan
    Hu, Jianhong
    Wang, Linghua
    Lupo, Philip J.
    Hicks, M. John
    Bonilla, Diana L.
    Dwyer, Karen C.
    Berres, Marie-Luise
    Poulikakos, Poulikos I.
    Merad, Miriam
    McClain, Kenneth L.
    Wheeler, David A.
    Allen, Carl E.
    Parsons, D. Williams
    [J]. BLOOD, 2014, 124 (19) : 3007 - 3015
  • [17] Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation
    Charles, Julie
    Beani, Jean-Claude
    Fiandrino, Giacomo
    Busser, Benoit
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (03) : E97 - E99
  • [18] Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients
    Chasset, Francois
    Barete, Stephane
    Charlotte, Frederic
    Cohen-Aubart, Fleur
    Arnaud, Laurent
    Le Pelletier, Francois
    Emile, Jean-Francois
    Frances, Camille
    Amoura, Zahir
    Haroche, Julien
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (03) : 513 - 520
  • [19] Chen Edward, 2016, JAAD Case Rep, V2, P369
  • [20] Cohen Aubart F, 2015, REV MED INTERNE, V36, pA40, DOI [10.1016/j.revmed.2015.03.267, DOI 10.1016/J.REVMED.2015.03.267]